Nelson Dusetti: Startups are essential in bridging scientific innovation and patient care
Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), reshared a post by Nicolas Wolikow, Chief Executive Officer and Founder of Cure51, on LinkedIn:
“Startups are essential in bridging scientific innovation and patient care.
The remarkable success of this collaboration once again demonstrates that perseverance and vision can overcome doubts and obstacles. The partnership between Cure51 and AP-HP marks a major milestone in pancreatic cancer research, bringing together top-tier expertise to push the boundaries of innovation.
Congratulations to Nicolas Wolikow, Simon Istolainen and the entire Cure51 team for this achievement and for uniting so many brilliant minds around such an ambitious project. Louis de Mestier, Pascal Hammel, Jean-Baptiste Bachet, Rémy Nicolle.”
Quoting Nicolas Wolikow‘s post:
“You’ll never make it”, “It’s too big for you”, “Their organisation is too bureaucratic”, “You’ll never convince their scientists”, “It’s too big an administrative machine”
There were many sceptics and haters, and fortunately, they were not listened to!
Magnificent collaboration with Greater Paris University Hospitals – AP-HP for the launch of our Rosalind Study with Hôpital Paul-Brousse, Hôpital Beaujon, Pitié Salpêtrière Hospital, Henri Mondor Hospital, and Saint-Antoine Hospital on the pancreatic cohort.
A very big thank you to Lauren Demerville and Sandrine Sagnes for their constant support throughout the implementation of the Firm.
It is a great honor for our teams to benefit from the scientific expertise of Professors Louis de Mestier, Pascal Hammel, and Jean-Baptiste Bachet, along with all the expert oncologists of Greater Paris University Hospitals – AP-HP.
None of this would have been possible without Elisabeth Auzias‘s incredible Cure51 task force, Anne Lecadieu and Laurene Villemey, with the support of Adrien Paix and Rémy Nicolle.
We can’t wait for the continuation, the launch of new indications, and the extension of our collaboration to new hospitals!
And a big acknowledgment to Marion Simon-Rainaud.”
More posts featuring Nelson Dusetti.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023